Source comparison
The Unvarnished Truth About Sermorelin vs Tesamorelin
Here's the honest answer: if your research question involves visceral fat, insulin sensitivity, or metabolic syndrome modeling, sermorelin won't deliver. The evidence gap is enormous. Tesamorelin has Phase III data showing 15% VAT reduction; sermorelin has non
This comparison does not assign a generated winner or score.
- Here's the honest answer: if your research question involves visceral fat, insulin sensitivity, or metabolic syndrome modeling, sermorelin won't deliver. The evidence gap is enormous. Tesamorelin has Phase III data showing 15% VAT reduction; sermorelin has none. Researchers select sermorelin for visceral fat studies because it's cheaper or because they assume all GHRH analogs work the same. They don't. Tesamorelin's structural modification isn't cosmetic. It fundamentally changes tissue distribution and receptor kinetics. If you're writing a grant targeting abdominal obesity or lipodystrophy and you list sermorelin as the intervention, reviewers who know the literature will notice. Match the peptide to the endpoint, or your protocol fails before the first injection.